Genetic Testing for CYP450 Polymorphisms to Predict Response to Clopidogrel: current evidence and test availability

PLoS Curr. 2010 Sep 20. pii: RRN1180.
Genetic Testing for CYP450 Polymorphisms to Predict Response to Clopidogrel: current evidence and test availability: Application: Pharmacogenomics.

Ned Mmsc Phd RM.

Office of Public Health Genomics, Centers for Disease Control and Prevention.

Abstract

The anti-platelet agent clopidogrel bisulfate (sold under the trade name Plavix in the United States) is a widely prescribed medication for the prevention of blood clots in patients with acute coronary syndrome, in those who have suffered other cardiovascular disease-related events such as ischemic stroke, and in patients who are undergoing percutaneous coronary intervention. Response to clopidogrel varies substantially due to genetic and acquired factors. Patients who experience recurrent cardiovascular ischemic or thrombotic events while taking clopidogrel are typically described as non-responsive or resistant. The drug's oxidation is mainly dependent on the cytochrome P450 enzyme 2C19 (CYP2C19). Patients with certain genetic variants in CYP2C19 have been found to have lower levels of the active metabolite, less platelet inhibition, and greater risk of major adverse cardiovascular events such as heart attack, stroke, and death. Testing for CYP2C19 polymorphisms may identify patients who will not respond adequately to the standard clopidogrel regimen and who should, consequently, be given an alternate treatment strategy. This article outlines the evidence concerning pharmacogenetic testing for clopidogrel response, including data on clinical validity and clinical utility, and summarizes the currently available tests marketed for this purpose.

PMID: 20877456 [PubMed - in process]PMCID: PMC2943252Free PMC Article

full-text:
Genetic Testing for CYP450 Polymorphisms to Predict Response to Clopidogrel: current evidence and test availability